Plasma tissue inhibitor of matrix metalloproteinase-1 (TIMP-1): An independent predictor of poor response to cardiac resynchronization therapy

European Journal of Heart Failure

Volumn 12, Issue 5, 2010, Pages 492-498

  Tolosana, Jose María ^a   Mont, Lluís ^a   Sitges, Marta ^a   Berruezo, Antonio ^a   Delgado, Victoria ^a   Vidal, Bàrbara ^a   Tamborero, David ^a   Morales, Manel ^a   Batlle, Montserrat ^a   Roig, Eulalia ^a   Castel, M Angeles ^a   Pérez Villa, Félix ^a   Godoy, Miguel ^a   Brugada, Josep ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Heart failure; Matrix metalloproteinase; Resynchronization therapy; Tissue inhibitor of matrix metalloproteinase

Indexed keywords

CREATININE; GELATINASE A; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIAC RESYNCHRONIZATION THERAPY DEVICE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME ASSAY; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HEART TRANSPLANTATION; HUMAN; INDEPENDENT VARIABLE; MALE; MULTIVARIATE ANALYSIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; WALKING; BLOOD; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DEFIBRILLATOR; DOPPLER ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY; ECHOGRAPHY; ENZYMOLOGY; EXERCISE TEST; HEALTH SURVEY; HEART FAILURE; HEART PACING; HEART VENTRICLE REMODELING; KAPLAN MEIER METHOD; METABOLISM; PATHOPHYSIOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; QUALITY OF LIFE; RISK; STATISTICS; TREATMENT FAILURE;

AGED; CARDIAC PACING, ARTIFICIAL; CONFIDENCE INTERVALS; DEFIBRILLATORS, IMPLANTABLE; ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY, DOPPLER, COLOR; EXERCISE TEST; FEMALE; HEALTH STATUS INDICATORS; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MATRIX METALLOPROTEINASE 2; MULTIVARIATE ANALYSIS; ODDS RATIO; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; QUALITY OF LIFE; STATISTICS AS TOPIC; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TREATMENT FAILURE; VENTRICULAR REMODELING; WALKING;

EID: 79957841396     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfq037     Document Type: Article

References (29)

1. Vardas PE, Auricchio A, Blanc JJ, Daubert JC, Drexler H, Ector H, Gasparini M, Linde C, Morgado FB, Oto A, Sutton R, Trusz-Gluza M, European Society of Cardiology; European Heart Rhythm Association. Guidelines for cardiac pacing and cardiac resynchronization therapy. Europace 2007;9:958-998.
2. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000;35:569-582. (Pubitemid 30167013)
3. Cohn JN, Johnson GR, Shabetai R, Loeb H, Tristani F, Rector T, Smith R, Fletcher R et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87(Suppl. VI): VI5-VI16. (Pubitemid 23164217)
4. Weber KT, Pick R, Janicki JS, Gadodia G, Lakier JB. Inadequate collagen tethers in dilated cardiopathy. Am Heart J 1988;116:1641-1646. (Pubitemid 19009878)
5. Gunja-Smith Z, Morales AR, Romanelli R, Woessner JF Jr. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinases and pyridinoline cross-links. Am J Pathol 1996;184:1639-1648. (Pubitemid 26135903)
6. Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145-2154.
7. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993;4:197-250. (Pubitemid 23103292)
8. Wilson EM, Gunasinghe HR, Coker ML, Sprunger P, Lee-Jackson D, Bozkurt B, Deswal A, Mann DL, Spinale FG. Plasma matrix metalloproteinase and Inhibitors Profiles in Patients with Heart failure. J Card Fail 2002;8:390-397.
9. Jordán A, Roldán V, García M, Monmeneu J, de Burgos FG, Lip GY, Marín F. Matrix metalloproteinase-1 and its inhibitor, TIMP-1, in systolic heart failure: Relation to functional data and prognosis. J Intern Med 2007;262:385-392. (Pubitemid 47246973)
10. George J, Patal S, Wexler D, Roth A, Sheps D, Keren G. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9 or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J 2005;150:484-487. (Pubitemid 41317618)
11. Díaz-Infante E, Mont L, Leal J, García-Bolao I, Fernández-Lozano I, Hernández-Madrid A, Pérez-Castellano N, Sitges M, Pavón-Jiménez R, Barba J, Cavero MA, Moya JL, Pérez-Isla L, Brugada J, SCARS Investigators. Predictors of lack of response to resynchronization therapy. Am J Cardiol 2005;95:1436-1440. (Pubitemid 40824763)
12. Vidal B, Sitges M, Marigliano A, Díaz-Infante E, Azqueta M, Tamborero D, Macías A, Roig E, Brugada J, Paré C, Mont L. Relation of response to cardiac resynchronization therapy to left ventricular reverse remodeling. Am J Cardiol 2006;97:876-881.
13. Molhoek SG, Bax JJ, Bleeker GB, Boersma E, van Erven L, Steendijk P, van der Wall EE, Schalij MJ. Comparison of response to cardiac resynchronization therapy in patients with sinus rhythm vs. chronic atrial fibrillation. Am J Cardiol 2004;94:1506-1509. (Pubitemid 40268451)
14. Lecoq G, Leclercq C, Leray E, Crocq C, Alonso C, de Place C, Mabo P, Daubert C. Clinical and electrocardiographic predictors of a positive response to cardiac resynchronization therapy in advance heart failure. Eur Heart J 2005;26:1094-1100. (Pubitemid 40839910)
15. Manolio TA, Baughman KL, Rodeheffer R, Pearson TA, Bristow JD, Michels VV, Abelmann WH, Harlan WR. Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute workshop). Am J Cardiol 1992;69:1458-1466.
16. Seward JB, Tajik AJ. Primary cardiomyopathies: classification, pathophysiology, clinical recognition and management. Cardiovasc Clin 1980;10:199-230. (Pubitemid 10001545)
17. Spinale FG. Matrix metalloproteinases. Regulation and dysregulation in the failing heart. Circ Res 2002;90:520-530. (Pubitemid 34640901)
18. Hessel MH, Bleeker GB, Bax JJ, Henneman MM, den Adel B, Klok M, Schalij MJ, Atsma DE, van der Laarse A. Reverse ventricular remodelling after cardiac resynchronization therapy is associated with a reduction in serum tenascin-C and plasma matrix metalloproteinase-9 levels. Eur J Heart Fail 2007;9:1058-1063. (Pubitemid 47451814)
19. Frantz S, Störk S, Michels K, Eigenthaler M, Ertl G, Bauersachs J, Angermann CE. Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: an independent predictor of mortality. Eur J Heart Fail 2008;10:338-395.
20. Garcia Bolao I, López B, Macias A, Gavira JJ, Azcárate P, Diez J. Impact of collagen type I turnover on the long-term response to cardiac resynchronization therapy. Eur Heart J 2008;29:898-906. (Pubitemid 351499498)
21. Jung K. A strong note of caution in using matrix metalloproteinase-1 and its inhibitor, TIMP-1 in serum as biomarkers in systolic heart failure. J intern Med 2008; (Epub ahead of print).
22. Gerlach RF, Tanus-Santos JE. Matriz Metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in congestive heart failure. Am Heart J 2006;152:e9. (Pubitemid 43974746)
23. Lovelock JD, Baker AH, Gao F, Dong JF, Bergeron AL, McPheat W, Sivasubramanian N, Mann DL. Heterogeneous effects of Tissue inhibitor of metalloproteinases on cardiac fibroblast. Am J Physiol Heart Circ Physiol 2005;288:H461-H468. (Pubitemid 40139626)
24. Mann DL. Inflammatory mediators and the failing heart. Past, present, and foreseeable future. Circ Res 2002;91:988-998. (Pubitemid 35416635)
25. Lindsay M, Maxwell P, Dunn FG. TIMP-1 a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 2002;40:136-141. (Pubitemid 34840088)
26. Schwartzkopff B, Fassbach M, Pelzer B, Brehm M, Strauer BE. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail 2002;4:439-444. (Pubitemid 36564961)
27. Tziakas DN, Chalikias GK, Papaioakeim M, Hatzinikolaou EI, Stakos DA, Tentes IK, Papanas N, Kortsaris A, Maltezos E, Hatseras DI. Comparison of levels of Matrix Metalloproteinase-2 and-3 in patients with ischemic cardiomyopathy vs. nonischemic cardiomyopathy. Am J Cardiol 2005;96:1449-1451. (Pubitemid 41566631)
28. Sundström J, Evans JC, Benjamin EJ, Levy D, Larson MG, Sawyer DB, Siwik DA, Colucci WS, Wilson PW, Vasan RS. Relation of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures. The Framingham heart study. Eur Heart J 2004;25:1509-1516. (Pubitemid 39165629)
29. West MJ, Nestel PJ, Kirby AC, Schnabel R, Sullivan D, Simes RJ, Pollicino Ch, Lubos E, Münzel TF, White HD, Tonkin AM, Bickel Ch, Tiret L, Blankerberg S, for the LIPID investigators. The Value of N-terminal fragment of brain natriuretic peptide and Tissue inhibitor of Metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study. Eur Heart J 2008;29:932-931.